|
| |
Epeius Biotechnologies CorporationEpeius Biotechnologies Corporation is a privately held biopharmaceutical company focused on research, development, and commercialization of the first truly effective targeted delivery system (TDS) that can be injected directly into a vein and deliver genes and/or molecular therapeutics preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic side effects or organ damage. These features make the targeted vectors more effective and less toxic than conventional medicines.
Targeted gene delivery, one of the primary applications of the company’s TDS technology, is considered to be the “holy grail” of gene therapy. Recently, Epeius Biotechnologies has achieved a highly significant milestone with its leading product, REXIN-GTM, which has been demonstrated to cause shrinkage and necrosis of tumors in human patients suffering from metastatic cancer. Further, REXIN-GTM is the first tumor-targeted injectable gene therapy vector that has been approved by both the U.S. FDA and the Philippine BFAD for use in Phase I/II clinical trials.
| Contact Details: |
| 475 Huntington Drive, |
| San Marino |
| California |
| 91108 |
| United States of America |
| Tel: | 626-441-6695 |
| Fax: | 626-441-6692 |
| Email: | info@epeiusbiotech.com |
| WWW: | www.epeiusbiotech.com/
|
|
Loading...
|
Recent Publications by Epeius Biotechnologies Corporation: |  |
The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
In an age where we can i) know precisely where a misplaced automobile... | 2nd September, 2009
| Epeius Biotechnologies Corporation, San Marino, CA 91108, USA.
| Int J Oncol. 2009 Aug;35(2):229-38.
|
Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
The advent of pathotropic (disease-seeking) targeting technologies,... | 14th November, 2008
| Oncology Research Unit, Epeius Biotechnologies Corporation, San Marino, CA
| Int J Oncol. 2008 Oct;33(4):665-75.
|
Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Metastatic cancer is a life-threatening illness with a predictably fatal... | 23rd December, 2006
| Epeius Biotechnologies Corporation, San Marino, CA 91108, USA.
| Int J Oncol. 2006 Nov;29(5):1053-64.
|
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Metastatic or non-resectable (stage IV) pancreatic cancer has a rapidly... | 18th August, 2004
| Epeius Biotechnologies Corporation, Glendale, CA 91203, USA.
| Int J Oncol. 2004 Jan;24(1):177-85.
|
Press Releases on Epeius Biotechnologies Corporation:
|
 |
| Epeius Biotechnologies to Partner at BIO Investor Forum |
20th October, 2009 |
Epeius Biotechnologies |
SAN FRANCISCO, Oct. 20 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and
|
| Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine |
12th October, 2009 |
Epeius Biotechnologies Corporation |
SAN MARINO, Calif., Oct. 12 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far
|
| Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer |
17th June, 2009 |
Epeius Biotechnologies |
SAN MARINO, Calif., June 17 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and
|
| Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 |
18th May, 2009 |
Epeius Biotechnologies |
SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent
|
| REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009) |
20th January, 2009 |
Epeius Bio |
SAN MARINO, Calif., Jan. 20 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 570 times since April 2007, the link to the organisation's website has been followed 79 times Recent Search Terms used to find this page: Oncology company San Marino CA | epeius biotechnologies corporation | Epeius Clinical Research Unit | epeius | EPEIUS BIOTECHNOLOGIES CORPORATION profile | location of epeius biotechnology in philippine | epius biotech | Epeius Biotechnologies Corporation | epeius BIOTECHNOLOGIES | california epeius biotechnology | . Search for more companies in San Marino Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Epeius Biotechnologies Corporation |
